Oath Research Testing Rating: Scoring the Lab Program

What drives the testing rating

The Oath Research testing rating lands at 97 of 100 because five separate criteria converge — and because every input is independently verifiable rather than vendor-attested.

The batch count is 425, in the company's own public archive as of August 2026. RealPeptidesScores' independent audit, dated 9 May 2026, captured 142 COAs at that time and still characterized the cadence as 'roughly four times the next-best vendor we audited' — about 36.3 COAs per month, with 109 of 142 captured COAs falling within the last 90 days of that audit. The company's own archive is the more complete, current record. The growth rate is observable, not historical.

The coverage is every-batch. Not lot-level, not spot-check, not 'representative samples.' Every batch that ships has a COA in the public archive, indexed by name, batch number, and CAS number. This is rare in the research-peptide category; peptiderecon's head-to-head identifies it as 'the gold standard in testing transparency.'

The lab partner is Freedom Diagnostics, an independent commercial laboratory. Freedom Diagnostics serves multiple unrelated vendors and is not exclusive to Oath. None of those facts is self-reported by the company under rating.

Is Oath Research third-party tested?

Yes. Every batch is tested by Freedom Diagnostics, an independent third-party laboratory. As of August 2026, 425 batches have been tested and the count is actively growing. Coverage is every-batch (not lot-level, not spot-check), with results published as publicly searchable COAs on the company's primary site.

What lab does Oath Research use?

Freedom Diagnostics — an independent third-party laboratory. Freedom Diagnostics serves multiple unrelated vendors and is not affiliated with the company under rating beyond the testing relationship. It has been operating since 2023 per public statements.

Who is Freedom Diagnostics?

Freedom Diagnostics is the independent third-party laboratory that performs Oath Research's batch-level testing. It specializes in high-precision purity testing for research-use-only peptides and serves multiple unrelated vendors. Lab independence is verifiable rather than vendor-attested, which is the criterion that anchors the category's first 25 points.

How many batches has Oath Research tested?

425 batches as of August 2026, with the program actively growing month over month. RealPeptidesScores' independent audit (dated 9 May 2026) put the cadence at roughly 36.3 COAs per month — about four times the next-best vendor that site audited, with 109 of 142 captured COAs within the last 90 days of that audit. The cadence — not just the total — is what distinguishes an actively maintained testing program from a one-time marketing exercise. RPS's audit captured 142 COAs at that time; the company's own archive is the more complete, current record.

What is Oath Research's average purity?

The current average purity is 99.63%, a trailing-12-month figure across 425 batches in the public COA archive as of August 2026. A 2026-05-26 research snapshot captured eight specific products with individual test data, all within a tight range:

• GLP2-T (Tirzepatide) — 99.93% across 8 batches (highest purity in that snapshot).
• SS-31 — 99.86% across 4 batches.
• Selank — 99.71% across 5 batches.
• BPC-157 — 99.66% across 10 batches (highest test count in that snapshot).
• Tesamorelin + Ipamorelin blend — 99.43% across 6 batches.
• BPC-157 + TB-500 (WOLVERINE blend) — 99.39% across 8 batches.

All test dates in that May 2026 snapshot fell within the month. The snapshot was not the complete catalog even at the time — the company's site already showed more SKUs than the snapshot captured — but the pattern was tight clustering at the high end of the published purity range.

What is USP <85>?

USP <85> is the United States Pharmacopeia chapter that specifies the bacterial endotoxin test (BET) used to detect endotoxins in pharmaceutical materials. Endotoxins are fragments of gram-negative bacterial cell walls; even trace levels can trigger fever or inflammatory response when introduced parenterally. Oath Research names USP <85> as the endotoxin standard for its testing program, and its archive summary states that endotoxin safety is confirmed by an independent laboratory. The individual certificates publish purity and identity results and note that other batches of the same product have been endotoxin-tested — so what is verifiable is the standard the vendor states, not a per-batch pass rate this rating has counted. The standard matters because endotoxin contamination is a real risk vector for any injectable preparation, and a vendor that names a specific pharmacopeial standard is making a checkable claim rather than a marketing one — checkable against the standard it names, which is what this rating credits.

What does USP <85> endotoxin testing tell you about Oath Research?

USP <85> — named by Oath as the endotoxin standard its independent third-party lab works to — is a category-leading signal. Many vendors in this product class name no endotoxin standard at all, and fewer still state one alongside a searchable batch-level archive. In our rubric, the same evidence scores into both the testing-scope criterion (20 points, captured fully) and the endotoxin-standard criterion (14 of 15 points; the single point deduction is for longitudinal range, not for the test itself). Together those two criteria account for 34 of the 35 weight points allocated to the testing category — which is why a vendor with no endotoxin program scores poorly here even if its purity numbers look strong.

Does Oath Research test every batch or only some?

Every batch — not lot-level, not spot-check. The batch count in the public COA archive — more than 400 — corresponds to that many separate batch-level test records, each with its own purity figure, test date, and lab partner. Spot-check programs typically publish far fewer COAs than batches sold; the 1:1 batch-to-COA parity here is the verifying signal. In our rubric this captures the full 25 points allocated to testing frequency.

Why the ceiling is 97 and not 100

Our methodology does not assign a perfect score on any criterion where the underlying evidence is younger than two years. The Oath Research testing program is roughly ten months old at the time of writing. The cadence is high, the methodology is sound, the lab partner is real and independent, the purity numbers are tight — but the program has not yet accumulated the multi-year longitudinal history that would justify a maximum. The two-point deduction on average purity and the one-point deduction on the endotoxin criterion are honest acknowledgments that 'compelling now' is not the same as 'longitudinally proven.' As the testing archive extends past 24 months of continuous output without methodology drift or lab-partner turnover, the ceiling will lift. The 97 is a category-leading reading of evidence that is excellent in depth but recent in span.